Teleflex Already Getting A Pretty Good Benefit Of The Doubt

Teleflex (NYSE:TFX) goes into 2023 needing to prove that the company can get the business growing back to a level more in line with investor expectations, and that includes the key UroLift product. The company has faced challenges including disrupted office visit trends and supply shortages, but the market is not going to be particularly forgiving if the business doesn’t start showing real acceleration over the next few quarters.

I can’t say that I’m all that bullish on the shares today. I think reaccelerating the UroLift business may be more challenging than management believes, and I’m concerned that the company is going to find itself challenged to meet Street growth expectations. M&A remains a wild card, and management has a good track record here, but I just don’t see the combination of growth and margins that would lead me to get all that excited about today’s valuation.

 

Read the full article here: 

Teleflex Already Getting A Pretty Good Benefit Of The Doubt